Samuel Dudley, Matthew Spence, Robert Frederick, Rosemary Stocks
{"title":"Postoperative Use of Ketorolac Improves Pain Management and Decreases Narcotic Use Following Primary Cleft Palate Surgery.","authors":"Samuel Dudley, Matthew Spence, Robert Frederick, Rosemary Stocks","doi":"10.1177/10556656211042168","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the efficacy and safety profile of ketorolac in cleft palate surgery.</p><p><strong>Design: </strong>Retrospective analysis of patients who underwent primary cleft palate surgery and received either postoperative ketorolac or opioids.</p><p><strong>Setting: </strong>Tertiary care children's hospital.</p><p><strong>Patients, participants: </strong>Eighty-nine patients enrolled who were all younger than 36 months of age, not dependent on a gastrostomy tube, with no history of bleeding disorders, and had undergone their primary cleft palate procedure by one specific surgeon between January 2010 and June 2019.</p><p><strong>Interventions: </strong>n/a.</p><p><strong>Main outcome measure: </strong>Morphine equivalent dose (MED), Face, Legs, Activity, Cry, Consolability (FLACC) score, length of stay (LOS), total oral intake (mL), total oral intake/LOS, and postoperative adverse events between ketorolac and no ketorolac groups.</p><p><strong>Results: </strong>MED, FLACC score, and LOS were significantly lower in the ketorolac group compared to the no ketorolac group. One patient in the ketorolac group had a bleeding event.</p><p><strong>Conclusions: </strong>Use of ketorolac significantly decreased narcotic usage and pain scores as reported by the FLACC score. Moreover, postoperative bleeding was rare in both ketorolac and no ketorolac groups.</p>","PeriodicalId":520794,"journal":{"name":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","volume":" ","pages":"1371-1376"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10556656211042168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Objective: To study the efficacy and safety profile of ketorolac in cleft palate surgery.
Design: Retrospective analysis of patients who underwent primary cleft palate surgery and received either postoperative ketorolac or opioids.
Setting: Tertiary care children's hospital.
Patients, participants: Eighty-nine patients enrolled who were all younger than 36 months of age, not dependent on a gastrostomy tube, with no history of bleeding disorders, and had undergone their primary cleft palate procedure by one specific surgeon between January 2010 and June 2019.
Interventions: n/a.
Main outcome measure: Morphine equivalent dose (MED), Face, Legs, Activity, Cry, Consolability (FLACC) score, length of stay (LOS), total oral intake (mL), total oral intake/LOS, and postoperative adverse events between ketorolac and no ketorolac groups.
Results: MED, FLACC score, and LOS were significantly lower in the ketorolac group compared to the no ketorolac group. One patient in the ketorolac group had a bleeding event.
Conclusions: Use of ketorolac significantly decreased narcotic usage and pain scores as reported by the FLACC score. Moreover, postoperative bleeding was rare in both ketorolac and no ketorolac groups.